Caliper Life Sciences Inc. launched a new imaging device that combines fluorescence, bioluminescence and X-ray imaging, aimed at developers of molecular drug therapies.
The Hopkinton, Mass.-based lab instruments maker said its IVIS Lumina XR in vivo imaging system works by combining optical fluorescent and bioluminescent images with co-registered digital X-ray images, thereby “enhancing the anatomical context of the optical molecular signals.”
That means, for example, that researchers could superimpose bioluminescent images of a tumor or infection over an X-ray or soft-tissue scan image.
Caliper posted second-quarter sales of $32.1 million, down 5.6 percent compared with the same period last year. But increased consumable sales, reduced inventory and cost-cutting measures brought the company closer to breaking even, with a net loss of $4.1 million on the three months ended June 30, compared with a net loss of $6.7 million during the second quarter of 2008, a 39.3 percent reduction.